Format

Send to

Choose Destination
Homeopathy. 2014 Oct;103(4):232-8. doi: 10.1016/j.homp.2014.06.001. Epub 2014 Jul 30.

Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer.

Author information

1
Université de Lyon, Hospices Civils de Lyon, Service d'Oncologie Médicale, CH Lyon-Sud, Pierre-Bénite, France. Electronic address: gilles.freyer@univ-lyon1.fr.
2
Centre d'Investigation des Therapeutiques en Onco-hématologie des HCL (CITOH - phase 1 - INCA), Unité de Coordination Onco-gériatrique de Lyon, Service d'Oncologie Médicale, CH Lyon-Sud, France.
3
BOIRON, 2 avenue de l'ouest lyonnais, 69510 Messimy, France.

Abstract

BACKGROUND:

Patients with advanced metastatic disease are often treated aggressively with multiple lines of chemotherapy, even in the last month of life. The benefit of such an approach remains uncertain. The objective of the study was to investigate whether Ruta graveolens 9c homeopathic medicine can improve quality of life (QoL) and tumour progression in patients with advanced cancer.

MATERIAL AND METHODS:

This was a single-centre, open-label, uncontrolled, pilot study. Patients (>18-years, life-expectancy ≥3 months, performance status ≤2) with locally-advanced solid tumours or metastases, previously treated with all available standard anti-cancer treatments were recruited. Oral treatment consisted of two 1-mL ampoules of Ruta graveolens (9c dilution) given daily for a minimum of 8 weeks, or until tumour and/or clinical progression. Primary outcome was QoL measured using the EORTC QLQ-C30 questionnaire. Secondary outcome measures were anxiety/depression measured using the Hospital Anxiety and Depression Scale (HADS), WHO performance status (PS), tumour progression assessed using RECIST criteria and tumour markers, survival and tolerance.

RESULTS:

Thirty-one patients were included (mean age: 64.3 years). Mean duration of treatment was 3.3 months (median: 2.1). QoL global health status improved significantly between baseline and week 8 (P < 0.001) and week 16 (P = 0.035), but was at the limit of significance (P = 0.057) at the end of the study. There was no significant change in anxiety/depression or PS during treatment. Ruta graveolens 9c had no obvious effect on tumour progression. Median survival was 6.7 months [95%CI: 4.8-14.9]. Ruta graveolens 9c was well-tolerated.

CONCLUSION:

Some patients treated with Ruta graveolens 9c had a transitory improvement in QoL, but the effectiveness of this treatment remains to be confirmed in further studies.

KEYWORDS:

Advanced cancer; Best supportive care; Pilot study; Quality of life; Ruta graveolens 9c; Treatment failure

PMID:
25439039
DOI:
10.1016/j.homp.2014.06.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for Elsevier Science
Loading ...
Support Center